|SERES THERAPEUTICS, INC. filed this Form 8-K on 10/16/2017|
SER-287 Phase 1b Ulcerative Colitis
study 58 mild-moderate UC patients failing standard of care* * Study designed to enroll 55 patients, with 15 in SER-287 treatment arms and 10 in the placebo / placebo arm Arm C: Placebo pre-treatment / SER-287 once weekly dosing for 8 weeks (n=15)
Arm A: Placebo pre-treatment / Placebo once daily for 8 weeks (n=11) Arm B: Vancomycin pre-treatment / SER-287 once daily dosing for 8 weeks (n=15) Arm D: Vancomycin pre-treatment / SER-287 once weekly dosing for 8 weeks (n=17)
© Seres Therapeutics. All Rights Reserved.